Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD Science Committee Report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 Mar 7. pii: 1900164. doi: 10.1183/13993003.00164-2019. [Epub ahead of print] Review.

PMID:
30846476
2.

Treatable Traits: a new paradigm for 21st century management of chronic airway diseases.

McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE, Marks GB, Bardin PP, Beasley R, Pavord ID, Wark PAB, Gibson PG; all the participants in the seminar.

Eur Respir J. 2019 Mar 7. pii: 1802058. doi: 10.1183/13993003.02058-2018. [Epub ahead of print] Review.

PMID:
30846468
3.

Fevipiprant, a selective prostaglandin-D2 receptor-2 antagonist, inhibits human group-2 innate lymphoid cell aggregation and function.

Hardman C, Chen W, Luo J, Batty P, Chen YL, Nahler J, Wu Y, Pavord ID, Erpenbeck VJ, Sandham DA, Xue L, Ogg G.

J Allergy Clin Immunol. 2019 Feb 27. pii: S0091-6749(19)30278-7. doi: 10.1016/j.jaci.2019.02.015. [Epub ahead of print]

PMID:
30825466
4.

DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment.

Saunders R, Kaul H, Berair R, Gonem S, Singapuri A, Sutcliffe AJ, Chachi L, Biddle MS, Kaur D, Bourne M, Pavord ID, Wardlaw AJ, Siddiqui SH, Kay RA, Brook BS, Smallwood RH, Brightling CE.

Sci Transl Med. 2019 Feb 13;11(479). pii: eaao6451. doi: 10.1126/scitranslmed.aao6451.

PMID:
30760581
5.

Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials: Bridging Clinical and Patient Perspectives.

Siddiqui S, Denlinger LC, Fowler SJ, Akuthota P, Shaw DE, Heaney LG, Brown L, Castro M, Winders TA, Kraft M, Wagers S, Peters MC, Pavord ID, Walker S, Jarjour NN.

Am J Respir Crit Care Med. 2019 Feb 6. doi: 10.1164/rccm.201809-1817PP. [Epub ahead of print]

PMID:
30726120
6.

Prospective observational study in patients with obstructive lung disease: NOVELTY design.

Reddel HK, Gerhardsson de Verdier M, Agustí A, Anderson G, Beasley R, Bel EH, Janson C, Make B, Martin RJ, Pavord I, Price D, Keen C, Gardev A, Rennard S, Sveréus A, Bansal AT, Brannman L, Karlsson N, Nuevo J, Nyberg F, Young SS, Vestbo J.

ERJ Open Res. 2019 Feb 1;5(1). pii: 00036-2018. doi: 10.1183/23120541.00036-2018. eCollection 2019 Feb.

7.

Inhaled Corticosteroid Therapy in Adult Asthma: Time for a New Therapeutic Dose Terminology.

Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID.

Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201810-1868CI. [Epub ahead of print]

PMID:
30645143
8.

Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST.

McKeever T, Mortimer K, Bradshaw L, Haydock R, Pavord I, Higgins B, Walker S, Wilson A, Price D, Thomas M, Devereux G, Brightling C, Renwick C, Parrott S, Mitchell E, Duley L, Harrison T.

Health Technol Assess. 2018 Dec;22(70):1-82. doi: 10.3310/hta22700.

9.

Correction: Synergistic activation of pro-inflammatory type-2 CD8 + T lymphocytes by lipid mediators in severe eosinophilic asthma.

Hilvering B, Hinks TSC, Stöger L, Marchi E, Salimi M, Shrimanker R, Liu W, Chen W, Luo J, Go S, Powell T, Cane J, Thulborn S, Kurioka A, Leng T, Matthews J, Connolly C, Borg C, Bafadhel M, Willberg CB, Ramasamy A, Djukanović R, Ogg G, Pavord ID, Klenerman P, Xue L.

Mucosal Immunol. 2019 Mar;12(2):581. doi: 10.1038/s41385-018-0121-5.

PMID:
30518781
10.

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.

Siddiqui SH, Pavord ID, Barnes NC, Guasconi A, Lettis S, Pascoe S, Petruzzelli S.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 6;13:3669-3676. doi: 10.2147/COPD.S179425. eCollection 2018.

11.

Exacerbations of severe asthma in patients treated with mepolizumab.

Shrimanker R, Pavord ID, Yancey S, Heaney LG, Green RH, Bradding P, Hargadon B, Brightling CE, Wardlaw AJ, Haldar P.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801127. doi: 10.1183/13993003.01127-2018. Print 2018 Dec. No abstract available.

PMID:
30464012
12.

Oral corticosteroid-dependent asthma: current knowledge and future needs.

Pavord ID.

Curr Opin Pulm Med. 2019 Jan;25(1):51-58. doi: 10.1097/MCP.0000000000000541.

PMID:
30461530
13.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
14.

Do we really need a new classification of airway diseases?

Agusti A, Pavord ID.

Lancet Respir Med. 2018 Dec;6(12):891-893. doi: 10.1016/S2213-2600(18)30386-2. Epub 2018 Nov 9. No abstract available.

PMID:
30420248
15.

Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma.

Heaney LG, Busby J, Bradding P, Chaudhuri R, Mansur AH, Niven R, Pavord ID, Lindsay JT, Costello RW.

Am J Respir Crit Care Med. 2019 Feb 15;199(4):454-464. doi: 10.1164/rccm.201806-1182OC.

PMID:
30339770
16.

Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study.

Kerkhof M, Tran TN, van den Berge M, Brusselle GG, Gopalan G, Jones RCM, Kocks JWH, Menzies-Gow A, Nuevo J, Pavord ID, Rastogi S, Price DB.

PLoS One. 2018 Jul 25;13(7):e0201143. doi: 10.1371/journal.pone.0201143. eCollection 2018.

17.

GLUCOLD, eosinophils and chronic obstructive pulmonary disease.

Pavord ID.

Respirology. 2018 Nov;23(11):966-967. doi: 10.1111/resp.13361. Epub 2018 Jun 26. No abstract available.

18.

Will precision medicine become an effective tool for airway disease?

Shrimanker R, Pavord ID.

Per Med. 2018 Jul 1;15(4):243-245. doi: 10.2217/pme-2018-0027. Epub 2018 Jun 21. No abstract available.

PMID:
29927347
19.

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, Schiller HB, Fischer R, Asciak R, Hallifax RJ, Mercer R, Dobson M, Dong T, Pavord ID, Collins GS, Kessler BM, Pass HI, Maskell N, Stathopoulos GT, Rahman NM.

Lancet Oncol. 2018 Jul;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8. Epub 2018 Jun 13.

PMID:
29908990
20.

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma.

Hilvering B, Hinks TSC, Stöger L, Marchi E, Salimi M, Shrimanker R, Liu W, Chen W, Luo J, Go S, Powell T, Cane J, Thulborn S, Kurioka A, Leng T, Matthews J, Connolly C, Borg C, Bafadhel M, Willberg CB, Ramasamy A, Djukanović R, Ogg G, Pavord ID, Klenerman P, Xue L.

Mucosal Immunol. 2018 Sep;11(5):1408-1419. doi: 10.1038/s41385-018-0049-9. Epub 2018 Jun 15. Erratum in: Mucosal Immunol. 2018 Dec 5;:.

PMID:
29907870
21.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

22.

Biologics and chronic obstructive pulmonary disease.

Pavord ID.

J Allergy Clin Immunol. 2018 Jun;141(6):1983-1991. doi: 10.1016/j.jaci.2018.04.020. Epub 2018 May 4.

PMID:
29729941
23.

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.

Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.

24.

Blood eosinophil levels as a biomarker in COPD.

Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, Barnes N, Hilton E.

Respir Med. 2018 May;138:21-31. doi: 10.1016/j.rmed.2018.03.016. Epub 2018 Mar 15. Review.

PMID:
29724389
25.

Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles.

Ghebre MA, Pang PH, Diver S, Desai D, Bafadhel M, Haldar K, Kebadze T, Cohen S, Newbold P, Rapley L, Woods J, Rugman P, Pavord ID, Johnston SL, Barer M, May RD, Brightling CE.

J Allergy Clin Immunol. 2018 Jun;141(6):2027-2036.e12. doi: 10.1016/j.jaci.2018.04.013. Epub 2018 Apr 28.

26.

The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised.

Pascoe S, Pavord I, Hinds D, Locantore N, Barnes N.

Lancet Respir Med. 2018 May;6(5):e18. doi: 10.1016/S2213-2600(18)30137-1. Epub 2018 Apr 5. No abstract available.

PMID:
29627194
27.

Associations between blood eosinophils and decline in lung function among adults with and without asthma.

Hancox RJ, Pavord ID, Sears MR.

Eur Respir J. 2018 Apr 19;51(4). pii: 1702536. doi: 10.1183/13993003.02536-2017. Print 2018 Apr.

PMID:
29563173
28.

Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations.

McKeever T, Mortimer K, Wilson A, Walker S, Brightling C, Skeggs A, Pavord I, Price D, Duley L, Thomas M, Bradshaw L, Higgins B, Haydock R, Mitchell E, Devereux G, Harrison T.

N Engl J Med. 2018 Mar 8;378(10):902-910. doi: 10.1056/NEJMoa1714257. Epub 2018 Mar 3.

29.

Mepolizumab for Eosinophilic COPD.

Sciurba FC, Bradford ES, Pavord ID.

N Engl J Med. 2018 Feb 15;378(7):681-683. doi: 10.1056/NEJMc1715454. No abstract available.

PMID:
29443666
30.

A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels.

Haughney J, Morice A, Blyth KG, Lee AJ, Coutts A, McKnight E, Pavord I.

Respir Med. 2018 Jan;134:117-123. doi: 10.1016/j.rmed.2017.12.001. Epub 2017 Dec 5.

PMID:
29413497
31.

COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV1 < 50% Predicted) COPD? No.

Pavord ID.

Chest. 2018 Apr;153(4):782-784. doi: 10.1016/j.chest.2018.01.030. Epub 2018 Feb 2. No abstract available.

PMID:
29410364
32.

Rebuttal From Dr Pavord.

Pavord ID.

Chest. 2018 Apr;153(4):786-787. doi: 10.1016/j.chest.2018.01.026. Epub 2018 Feb 2. No abstract available.

PMID:
29410251
33.

'We can't diagnose asthma until <insert arbitrary age>'.

Bush A, Pavord ID.

Arch Dis Child. 2018 Aug;103(8):729-731. doi: 10.1136/archdischild-2017-314180. Epub 2018 Jan 5. No abstract available.

34.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

35.

Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.

Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):874-882.e4. doi: 10.1016/j.jaip.2017.11.026. Epub 2017 Dec 16.

36.

Physiotherapy breathing retraining for asthma: a randomised controlled trial.

Bruton A, Lee A, Yardley L, Raftery J, Arden-Close E, Kirby S, Zhu S, Thiruvothiyur M, Webley F, Taylor L, Gibson D, Yao G, Stafford-Watson M, Versnel J, Moore M, George S, Little P, Djukanovic R, Price D, Pavord ID, Holgate ST, Thomas M.

Lancet Respir Med. 2018 Jan;6(1):19-28. doi: 10.1016/S2213-2600(17)30474-5. Epub 2017 Dec 14.

37.

Biomarkers for severe eosinophilic asthma.

Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, Pavord I.

J Allergy Clin Immunol. 2017 Dec;140(6):1509-1518. doi: 10.1016/j.jaci.2017.10.005. Review.

38.

Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis.

Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D.

NPJ Prim Care Respir Med. 2017 Dec 5;27(1):65. doi: 10.1038/s41533-017-0063-5.

39.

Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma.

Hinks TSC, Batty P, Klenerman P, Pavord ID, Xue L.

Am J Respir Cell Mol Biol. 2017 Dec;57(6):745-747. doi: 10.1165/rcmb.2017-0201LE. No abstract available.

40.

The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Cooper CB, Brusselle G, Pascoe SJ, Pavord ID.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):967-968. doi: 10.1164/rccm.201709-1797LE. No abstract available.

PMID:
29140724
41.

Treating asthma exacerbations in athletes: TUE or not TUE?

Hull JH, Pavord ID.

Lancet Respir Med. 2018 Jan;6(1):8-10. doi: 10.1016/S2213-2600(17)30428-9. Epub 2017 Oct 30. No abstract available.

PMID:
29097025
42.

Precision medicine in airway diseases: moving to clinical practice.

Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, Louis R, McDonald VM, Sterk PJ, Thomas M, Vogelmeier C, Pavord ID; on behalf of all participants in the seminar.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701655. doi: 10.1183/13993003.01655-2017. Print 2017 Oct.

PMID:
29051276
43.

A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults.

Thomas M, Bruton A, Little P, Holgate S, Lee A, Yardley L, George S, Raftery J, Versnel J, Price D, Pavord I, Djukanovic R, Moore M, Kirby S, Yao G, Zhu S, Arden-Close E, Thiruvothiyur M, Webley F, Stafford-Watson M, Dixon E, Taylor L.

Health Technol Assess. 2017 Sep;21(53):1-162. doi: 10.3310/hta21530.

44.

After asthma: redefining airways diseases.

Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, Cullinan P, Custovic A, Ducharme FM, Fahy JV, Frey U, Gibson P, Heaney LG, Holt PG, Humbert M, Lloyd CM, Marks G, Martinez FD, Sly PD, von Mutius E, Wenzel S, Zar HJ, Bush A.

Lancet. 2018 Jan 27;391(10118):350-400. doi: 10.1016/S0140-6736(17)30879-6. Epub 2017 Sep 11. Review. No abstract available.

45.

After the asthmas: Star Wars and Star Trek.

Bush A, Pavord ID.

Eur Respir J. 2017 Sep 12;50(3). pii: 1701362. doi: 10.1183/13993003.01362-2017. Print 2017 Sep. No abstract available.

46.

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.

Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC.

N Engl J Med. 2017 Oct 26;377(17):1613-1629. doi: 10.1056/NEJMoa1708208. Epub 2017 Sep 11.

47.

Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial.

Morice AH, McGarvey L, Pavord ID, Higgins B, Chung KF, Birring SS.

J Thorac Dis. 2017 Jul;9(7):1864-1872. doi: 10.21037/jtd.2017.06.18.

48.

Multidimensional assessment of severe asthma: A systematic review and meta-analysis.

Clark VL, Gibson PG, Genn G, Hiles SA, Pavord ID, McDonald VM.

Respirology. 2017 Oct;22(7):1262-1275. doi: 10.1111/resp.13134. Epub 2017 Aug 3. Review.

49.

Blood eosinophil count and exacerbation risk in patients with COPD.

Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agustí A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, Popov T, Roche N, Ryan D, Thomas M, Vogelmeier C, Chisholm A, Freeman D, Bafadhel M, Hillyer EV, Price DB.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700761. doi: 10.1183/13993003.00761-2017. Print 2017 Jul. No abstract available.

50.

The Objective Assessment of Cough Frequency in Bronchiectasis.

Spinou A, Lee KK, Sinha A, Elston C, Loebinger MR, Wilson R, Chung KF, Yousaf N, Pavord ID, Matos S, Garrod R, Birring SS.

Lung. 2017 Oct;195(5):575-585. doi: 10.1007/s00408-017-0038-x. Epub 2017 Jul 13.

Supplemental Content

Loading ...
Support Center